AMP German Cannabis Group Receives Irradiation Licence for Medical Cannabis Imports into Germany

Home / Press Release  / AMP German Cannabis Group Receives Irradiation Licence for Medical Cannabis Imports into Germany

BERLIN, Germany, April 14, 2020 – AMP German Cannabis Group Inc. (“AMP” or the “Company”) (CSE: XCX) (FSE: C4T, ISIN: CA00176G1028) is pleased to announce it has successfully obtained all the required licences to import, store at its licensed narcotic storage facility and distribute to its pharmaceutical distributors irradiated EU-GMP certified medical cannabis flower.
The Federal Institute for Drugs and Medical Devices (BfArM) granted an irradiation permit to AMP Alternative Medical Products GmbH (“AMP Germany”), a wholly-owned subsidiary of AMP, for the distribution of medical cannabis flowers that have undergone ionizing radiation treatment (“AMRadV License”).
EU-GMP medical cannabis imported into Germany that does not comply with microbial levels as defined in general monographies of the European Pharmacopoeia must use microbial sterilization before being made available for sale in Germany’s medical cannabis program. To date, all medical cannabis imported into Germany has been irradiated and requires an AMRadV License.
Dr. Stefan Feuerstein, President of AMP, commented: “Being granted an AMRadV Licence is an important and last step for AMP to be able to import from Europe and elsewhere. AMP will now complete the EU-GMP certification audit of its supply chain and start the process with the Netherlands Ministry of Health who supplies and organizes the export of medical cannabis flowers from the Netherlands. AMP is planning to start imports from the Netherlands in May and Canada during the latter part of this year.”